Aug 14, 2023 7:00am EDT Skye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
Jul 13, 2023 7:00am EDT Skye Bioscience Receives Positive Safety Review for Final Cohort of Fully-Enrolled Phase 1 Study of SBI-100 Ophthalmic Emulsion
Jul 06, 2023 7:00am EDT Skye Bioscience Completes Production and Filling of Investigational Drug Material in Preparation for Phase 2a Glaucoma Clinical Trial
Jun 12, 2023 7:00am EDT Skye Bioscience Completes Enrollment of Phase 1 Clinical Trial of Novel CB1R Agonist, SBI-100 Ophthalmic Emulsion
Jun 02, 2023 7:00am EDT Skye Bioscience Receives Positive Safety Review of Fifth Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsion
May 17, 2023 7:00am EDT Skye Bioscience Begins Dosing Fifth of Six Cohorts in Phase 1 Clinical Trial of Novel CB1R Agonist
May 15, 2023 7:00am EDT Skye Bioscience Receives Positive Safety Review in First Multiple-Administration Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsion
Apr 27, 2023 7:00am EDT Skye Bioscience Begins Dosing Phase 1 Fourth Cohort in Clinical Trial of Novel CB1R Agonist
Apr 04, 2023 7:00am EDT Skye Bioscience Receives Positive Safety Review of Third Cohort in Phase 1 Study of SBI-100 Ophthalmic Emulsion
